The Vioxx recall is just the latest of several episodes this year that have prompted criticism of the FDA and Senate hearings. A panel talks about the drug approval process, post-marketing safety surveillance, and how the agency’s work affects Americans’ health and safety.

Guests

  • Dr. Jerry Avorn author of "Powerful Medicines," professor of medicine at Harvard Medical School, and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital in Boston
  • Sen. Charles Grassley (R-Iowa), ranking member of the Senate Finance Committee
  • Marc Kaufman reporter on the national desk of "The Washington Post"
  • Alan Goldhammer, PhD associate vice president for regulatory affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA)
  • Dr. Sandra Kweder deputy director of the FDA's Office of New Drugs

Related Links

Topics + Tags

Comments

comments powered by Disqus
Most Recent Shows

Rating The United States On Child Care

Thursday, Sep 29 2016A majority of parents in the U.S. work outside the home. That means about 12 million children across the country require care. A new report ranks states on cost, quality and availability of child care - and says nobody is getting it right.